Patents Examined by Brad Duffy
  • Patent number: 11951173
    Abstract: An antibody-drug conjugate (ADC) or a pharmaceutically acceptable salt thereof, is provided. The ADC includes a tetravalent monoclonal antibody conjugated to a cytotoxic drug by a chemical linker. The monoclonal antibody includes two long chains and four short chains. Each of the long chains includes a first segment and a second segment, the first segment located proximal to the N-terminus of the long chain, and the second segment located proximal to the C-terminus of the long chain. Each of the first segment and second segment pairs with one of the short chains to form an antigen-binding fragment domain, therefore forming four antigen-binding fragment domains having specificity toward the same antigen. Pharmaceutical composition including the ADC and methods of treating diseases using the compositions are also provided.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: April 9, 2024
    Assignee: Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
    Inventors: Yuhong Zhou, Ziping Wei
  • Patent number: 11951129
    Abstract: Disclosed are compositions and methods for targeted treatment of CLEC12A-expressing cancers. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to target and kill CLEC12A-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a CLEC12A-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs. Also disclosed are multivalent antibodies are disclosed that are able to engage T-cells to destroy CLEC12A-expressing malignant cells.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: April 9, 2024
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventor: Marco L. Davila
  • Patent number: 11945878
    Abstract: The present invention relates to a switch molecule for activating a chimeric antigen receptor effector cell, to a polypeptide or fusion protein binding thereto, and to a chimeric antigen receptor. (i) When a switch molecule of the present invention is used, in order to improve safety of a CAR-T cell, if severe toxicity appears, a switch molecule lacking a targeting moiety can be injected to adjust activation of the CAR-T cell. (ii) When an antigen is mutated, or in order to cure various carcinomas, instead of an existing switch molecule, a switch molecule targeting a new antigen generated due to the mutation or a switch molecule targeting a different tumor associated antigen (TAA) can be injected into a patient to cure cancer more effectively.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: April 2, 2024
    Assignee: ABCLON INC.
    Inventors: Jong Seo Lee, Carl Erik Mathias Uhlen
  • Patent number: 11939391
    Abstract: The present invention provides a therapeutic agent for the treatment, prevention and diagnosis of cancers associated with cells that overexpressing transferrin receptor 1 (TfR1) and its variants on the cell surface, including but not limited to AML, ALL, lymphoma, multiple myeloma, breast cancer, gastric cancer, glioblastoma, prostate cancer, urothelial bladder cancer, pancreatic cancer, esophageal cancer, colorectal cancer, ovarian cancer, liver cancer. The agent is based on the amino acid sequences of the novel light chain and heavy chain variable regions of an anti-TfR1 monoclonal antibody (mAb), MAb11-22.1, which, is highly specific for tumor cells and in an ADC form, can functionally inhibit the proliferation of several human cancer cell lines and the growth of AML cell line-derived xenograft tumors in mouse models.
    Type: Grant
    Filed: December 6, 2021
    Date of Patent: March 26, 2024
    Assignee: MEDABOME, INC.
    Inventors: Mason Lu, Qinhong Ma
  • Patent number: 11939394
    Abstract: The invention provides means and methods for inhibiting growth of a cancer. The means in some embodiments comprise proteins and antibodies that binds an extracellular part of a membrane associated member of the epidermal growth factor (EGF) receptor family and an extracellular part of a membrane associated member of a WNT signaling pathway. Further provided are various cells and assays that are helpful in the production of the proteins, antibodies and cells.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: March 26, 2024
    Assignees: Merus N.V., Fundacio Institut de Recerca Biomedica, InstituciĆ³ Catalana de Recerca I Estudis Avancats
    Inventors: Mark Throsby, Ton Logtenberg, Johannes Carolus Clevers, Robert Gerhardus Jacob Vries, Eduard Batlle, Bram Herpers
  • Patent number: 11919959
    Abstract: The invention provides a method of inhibiting angiogenesis in an individual, the method comprising administering to the individual an agent that inhibits the interaction between CLEC14A and MMRN2. The inhibitor may be an antibody, a polypeptide, a peptide, a polynucleotide, a peptidomimetic, a natural product, a carbohydrate, an aptamer or a small molecule.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: March 5, 2024
    Assignee: Cancer Research Technology Limited
    Inventors: Roy Bicknell, Peter Noy, Kabir Ali Khan
  • Patent number: 11884734
    Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to MET, a receptor tyrosine kinase, and modulate the expression and/or activity of MET. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer. In one aspect, provided herein is a monoclonal antibody or antigen-binding fragment thereof that binds to the Sema/PSI domain of human MET. Also provided herein is a kit comprising an antibody or antigen-binding fragment provided herein. Also provided herein is a method of managing, protecting against, or treating cancer in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment provided herein.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: January 30, 2024
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Yan Yang, Sreekala Mandiyan, Brett Robinson, Lida Kimmel, Yaron Hadari, Timothy David Jones, Francis Joseph Carr, Robert George Edward Holgate, Richard Weldon
  • Patent number: 11866478
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor (e.g., a G-protein coupled receptor family C group 5 member D (GPRC5D)), and immunoresponsive cells comprising such CARs. The presently disclosed CARs targeting a G-protein coupled receptor (e.g., GPRC5D) have enhanced immune-activating properties, including anti-tumor activity.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: January 9, 2024
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L Smith, Cheng Liu
  • Patent number: 11857571
    Abstract: Antigen binding fragments, chimeric antigen receptors, and bi-specific T-cell engagers having specificity for MICA and methods for using the same in the diagnosis and treatment of disorders associated with MICA and/or MICB expression are provided.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: January 2, 2024
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Charles Sentman, Michael Battles
  • Patent number: 11833174
    Abstract: Embodiments relate to a modified cell comprising a polynucleotide encoding a dominant negative form of Death receptor 5 (DR5). In embodiments, the modified cell further comprises a chimeric antigen receptor (CAR) and/or a modified TCR.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: December 5, 2023
    Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.
    Inventors: Zhiyuan Cao, Chengfei Pu, Dongqi Chen, Wei Ding
  • Patent number: 11820806
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor (e.g., a G-protein coupled receptor family C group 5 member D (GPRC5D)), and immunoresponsive cells comprising such CARs. The presently disclosed CARs targeting a G-protein coupled receptor (e.g., GPRC5D) have enhanced immune-activating properties, including anti-tumor activity.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: November 21, 2023
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
  • Patent number: 11814436
    Abstract: Antibodies, fragments thereof, and chimeric proteins comprising same are presented that have specific binding activity against CD30. Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals diagnosed with hematopoietic malignancies, including Hodgkin lymphoma, CD30-positive B cell lymphomas, CD30-positive T cell lymphomas, CD30-positive NK cell lymphomas.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: November 14, 2023
    Assignee: NantBio, Inc.
    Inventors: Clifford Anders Olson, Kayvan Niazi, Helty Adisetiyo, Hermes J. Garban, Mark Guido, Heather McFarlane, Tan Trinh, Shiho Tanaka
  • Patent number: 11788059
    Abstract: Provided herein are NK-92 cells expressing at least one CAR and at least one Fc receptor. Also provided are methods of treatment of a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient NK-92-Fc-CAR.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: October 17, 2023
    Assignee: Immunity Bio, Inc.
    Inventor: Tien Lee
  • Patent number: 11773146
    Abstract: As disclosed herein, stapled peptides targeting the interaction interface between proteins that maintain the integrity of Wiskott-Aldrich syndrome protein family member 3 (WASF3) leads to destabilization of WASF3 and suppression of invasion. Disclosed are stapled peptides that inhibit the binding of Cytoplasmic FMR1-interacting protein 1 (CYFIP1) to either WASF3 or NCK-associated protein (NCKAP1). Also disclosed are methods for treating or suppressing invasion and metastasis of a cancer in a subject that involve administering to the subject a therapeutically effective amount of a stapled peptide disclosed herein.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: October 3, 2023
    Assignees: University of Georgia Research Foundation, Inc., Augusta University Research Institute
    Inventors: Eileen J. Kennedy, John Cowell
  • Patent number: 11752204
    Abstract: The present invention provides vaccines comprising carbohydrate antigen conjugated to a diphtheria toxin (DT) as a carrier protein, wherein the ratio of the number of carbohydrate antigen molecule to the carrier protein molecule is higher than 5:1. Also disclosed herein is a novel saponin adjuvant and methods to inhibit cancer cells, by administering an effective amount of the vaccine disclose herein.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: September 12, 2023
    Assignee: OBI PHARMA INC.
    Inventors: Wei-Han Lee, Nan-Hsuan Wang, Chung-Hao Chang, Yih-Huang Hsieh, Cheng-Der Tony Yu, Cheng-Chi Wang, Yu-Hsin Lin, Yu-Chen Lin, I-Ju Chen
  • Patent number: 11739148
    Abstract: The invention is among others concerned with human CD3 binding antibodies comprising a heavy chain and light chain wherein said heavy chain comprises a variable region that comprises the amino acid sequence: QVQLV QSGGG VVQPG RSLRL SCVAS GFTFS SYGMH WVRQA PGKGL EWVAA IWYX1X2RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT GYNWF DPWGQ GTLVT VSS with 0-5 amino acid insertions, deletions, substitutions, additions or a combination thereof at one or more positions other than the position indicated by X1X2; wherein X1=N and X2=A; X1=N and X2=T; X1=S and X2=G; X1=H and X2=G; X1=D and X2=G; or X1=H and X2=A. The invention is also concerned with bispecific antibodies that have a heavy chain as defined herein above. The invention is also concerned with methods of production of the antibody, cells producing the antibody and with (medical) uses of the antibody.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 29, 2023
    Assignee: Merus N.V.
    Inventors: Alexander Berthold Hendrik Bakker, Pieter Fokko Van Loo
  • Patent number: 11718680
    Abstract: The present invention relates to combination therapies employing anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: August 8, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Claudia Ferrara Koller, Christian Klein, Mario Perro, Johannes Sam, Pablo UmaƱa, Wei Xu
  • Patent number: 11713358
    Abstract: The present invention relates to bispecific chimeric polypeptide assembly compositions comprising bulking moieties linked to binding domains by cleavable release segments that, when cleaved are capable of concurrently binding effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable chimeric polypeptide assembly compositions.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: August 1, 2023
    Assignee: AMUNIX PHARMACEUTICALS, INC.
    Inventors: Volker Schellenberger, Fan Yang, Desiree Thayer, Bee-Cheng Sim, Chia-Wei Wang
  • Patent number: 11684656
    Abstract: A new approach for the treatment of a malignant disease is provided. The new method comprises administering a traditional anti-cancer therapy in combination with a DNA or protein vaccine comprising CTLA-4 and PD-1, or a DNA or protein vaccine comprising CTLA-4 and PD-L1.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: June 27, 2023
    Assignee: TAIPEI VETERANS GENERAL HOSPITAL
    Inventors: Keng-Li Lan, Yi-Sheng Shih, Keng-Hsueh Lan, Sung-Hsin Kuo, Weng-Shiang Chen
  • Patent number: 11673937
    Abstract: The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 13, 2023
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventors: Dario Campana, Chihaya Imai